1-11 of 11
Charles Dumontet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Available to Purchase
Eileen M. Boyle, Cody Ashby, Ruslana G. Tytarenko, Shayu Deshpande, Hongwei Wang, Yan Wang, Adam Rosenthal, Jeffrey Sawyer, Erming Tian, Erin Flynt, Antje Hoering, Sarah K. Johnson, Michael W. Rutherford, Christopher P. Wardell, Michael A. Bauer, Charles Dumontet, Thierry Facon, Sharmilan Thanendrarajan, Carolina D. Schinke, Maurizio Zangari, Frits van Rhee, Bart Barlogie, David Cairns, Graham Jackson, Anjan Thakurta, Faith E. Davies, Gareth J. Morgan, Brian A. Walker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2422–2432.
https://doi.org/10.1158/1078-0432.CCR-19-1507
Published: 15 May 2020
View articletitled, BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Open the PDF for BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

Free
Florence Magrangeas, Rowan Kuiper, Hervé Avet-Loiseau, Wilfried Gouraud, Catherine Guérin-Charbonnel, Ludovic Ferrer, Alexandre Aussem, Haytham Elghazel, Jérôme Suhard, Henri Der Sakissian, Michel Attal, Nikhil C. Munshi, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, Loïc Campion, Stéphane Minvielle
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4350–4355.
https://doi.org/10.1158/1078-0432.CCR-15-3163
Published: 31 August 2016
View articletitled, A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Open the PDF for A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Free
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Goldmacher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, Véronique Blanc
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4574–4583.
https://doi.org/10.1158/1078-0432.CCR-14-0695
Published: 01 September 2014
View articletitled, SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Open the PDF for SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors

Free
Inès Tagoug, Lars Petter Jordheim, Stéphanie Herveau, Eva-Laure Matera, Anne-Laure Huber, Kamel Chettab, Serge Manié, Charles Dumontet
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3556–3566.
https://doi.org/10.1158/1078-0432.CCR-12-3134
Published: 30 June 2013
View articletitled, Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors
Open the PDF for Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors in another window
Includes: Supplementary data
Journal Articles

BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy

Free
Charles Dumontet, Maryla Krajewska, Isabelle Treilleux, John R. Mackey, Miguel Martin, Mathieu Rupin, Laurence Lafanechère, John C. Reed
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3988–3997.
https://doi.org/10.1158/1078-0432.CCR-10-0079
Published: 28 July 2010
View articletitled, BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy
Open the PDF for BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

In vivo Model of Follicular Lymphoma Resistant to Rituximab

Free
Stéphane Dalle, Sophie Dupire, Stéphanie Brunet-Manquat, Lina Reslan, Adriana Plesa, Charles Dumontet
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 851–857.
https://doi.org/10.1158/1078-0432.CCR-08-1685
Published: 02 February 2009
View articletitled, In vivo Model of Follicular Lymphoma Resistant to Rituximab
Open the PDF for In vivo Model of Follicular Lymphoma Resistant to Rituximab in another window
Journal Articles

Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

Free
Carlos M. Galmarini, Isabelle Treilleux, Fatima Cardoso, Chantal Bernard-Marty, Virginie Durbecq, David Gancberg, Marie-Christine Bissery, Marianne Paesmans, Denis Larsimont, Martine J. Piccart, Angelo Di Leo, Charles Dumontet
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4511–4516.
https://doi.org/10.1158/1078-0432.CCR-07-4741
Published: 15 July 2008
View articletitled, Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
Open the PDF for Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel in another window
Includes: Supplementary data
Journal Articles

Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10

Free
Pascal Sève, Raymond Lai, Keyue Ding, Timothy Winton, Charles Butts, John Mackey, Charles Dumontet, Laith Dabbagh, Sarit Aviel-Ronen, Lesley Seymour, Marlo Whitehead, Ming-Sound Tsao, Frances A. Shepherd, Tony Reiman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 994–999.
https://doi.org/10.1158/1078-0432.CCR-06-1503
Published: 08 February 2007
View articletitled, Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10
Open the PDF for Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10 in another window
Journal Articles

Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy

Free
Pascal Sève, Sylvie Isaac, Olivier Trédan, Pierre-Jean Souquet, Yves Pachéco, Maurice Pérol, Laurence Lafanéchère, Aurélie Penet, Eva-Laure Peiller, Charles Dumontet
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5481–5486.
https://doi.org/10.1158/1078-0432.CCR-05-0285
Published: 01 August 2005
View articletitled, Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy
Open the PDF for Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy in another window
Journal Articles

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

Free
Jennifer Spratlin, Randeep Sangha, Darryl Glubrecht, Laith Dabbagh, James D. Young, Charles Dumontet, Carol Cass, Raymond Lai, John R. Mackey
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (20): 6956–6961.
https://doi.org/10.1158/1078-0432.CCR-04-0224
Published: 22 October 2004
View articletitled, The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma
Open the PDF for The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma in another window
Journal Articles

Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug

Free
Lars Petter Jordheim, Emeline Cros, Marie-Hélène Gouy, Carlos M. Galmarini, Suzanne Peyrottes, John Mackey, Christian Perigaud, Charles Dumontet
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5614–5621.
https://doi.org/10.1158/1078-0432.CCR-04-0506
Published: 24 August 2004
View articletitled, Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug
Open the PDF for Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug in another window